)
Visual
test
InMed Pharmaceuticals
InMed Pharmaceuticals (INM) investor relations material
InMed Pharmaceuticals Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary20 Mar, 2026
Company overview and business model
Develops proprietary small molecule drug candidates targeting CB1 and CB2 receptors for diseases with high unmet medical needs.
Focuses on pharmaceutical R&D, leveraging the endocannabinoid system for therapeutic applications.
Incorporated in British Columbia, Canada, with a history of executive and business sector changes since 1981.
Financial performance and metrics
Aggregate market value of common stock held by non-affiliates is approximately $2.6 million as of March 18, 2026.
Audit reports highlight recurring losses, negative cash flows, and an accumulated deficit, raising substantial doubt about ability to continue as a going concern.
Use of proceeds and capital allocation
Net proceeds intended for general corporate purposes, including working capital, operating expenses, and capital expenditures.
May use proceeds to repay debt or acquire/invest in complementary businesses, products, or technologies, though no current commitments exist.
Unallocated funds may be invested in marketable securities and short-term investments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from InMed Pharmaceuticals
- Lead Alzheimer's candidate shows robust preclinical results; clinical trials targeted for 2027.INM
Sidoti March Small-Cap Virtual Conference18 Mar 2026 - Revenue dropped 26% as INM-901 advanced, with cash reserves and regulatory risks in focus.INMQ2 202612 Feb 2026
- Promising preclinical data in Alzheimer's and dry AMD, with strong financial and commercial support.INMEmerging Growth Conference 723 Feb 2026
- INM-901 and precision medicine are driving advances in Alzheimer's therapy and research.INMStatus Update14 Jan 2026
- INM-901 shows strong preclinical promise for Alzheimer's, with commercial revenue supporting R&D.INMH.C. Wainwright 27th Annual Global Investment Conference31 Dec 2025
- Promising preclinical results in Alzheimer's and dry AMD drive focus on partnerships and 2026 milestones.INMLife Sciences Virtual Investor Forum 202512 Dec 2025
- Shareholders will vote on director elections, auditor re-appointment, and a major share issuance.INMProxy Filing1 Dec 2025
- Shareholders to vote on issuing 20%+ new shares under SEPA, potentially diluting ownership.INMProxy Filing1 Dec 2025
- Shareholders are asked to approve a major share issuance under SEPA, potentially diluting ownership.INMProxy Filing1 Dec 2025
Next InMed Pharmaceuticals earnings date
Q3 202612 May, 2026
InMed Pharmaceuticals
Next InMed Pharmaceuticals earnings date
Q3 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage